4.7 Article

Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus Aureus Infections in Adults and Children

Journal

CLINICAL INFECTIOUS DISEASES
Volume 52, Issue 3, Pages E18-E55

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciq146

Keywords

-

Funding

  1. Cubist
  2. Ortho-McNeil
  3. Pfizer
  4. Theravance
  5. Targanta
  6. Astellas
  7. AdvanDx
  8. Clorox
  9. Sanofi Pasteur
  10. Sage
  11. GeneOhm
  12. Cubist Pharmaceuticals
  13. Merck
  14. Wyeth
  15. Johnson Johnson
  16. Sanofi-Aventis
  17. Vicuron Pharmaceuticals
  18. Wyeth-Ayerst
  19. Theravance/Astellas

Ask authors/readers for more resources

Evidence-based guidelines for the management of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections were prepared by an Expert Panel of the Infectious Diseases Society of America (IDSA). The guidelines are intended for use by health care providers who care for adult and pediatric patients with MRSA infections. The guidelines discuss the management of a variety of clinical syndromes associated with MRSA disease, including skin and soft tissue infections (SSTI), bacteremia and endocarditis, pneumonia, bone and joint infections, and central nervous system (CNS) infections. Recommendations are provided regarding vancomycin dosing and monitoring, management of infections due to MRSA strains with reduced susceptibility to vancomycin, and vancomycin treatment failures.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available